Healthcare > Clinical Trials3/25/2024 3:00 PM
The tumor microenvironment is a complex mix of cancer cells, immune cells, and other components that all play a part in tumor progression, metastasis, and therapy responses. Understanding the highly dynamic nature of the tumor microenvironment and the factors that influence those changes is essential for developing effective precision oncology therapies. Innovations in computational pathology and artificial intelligence, coupled with novel multiplex biomarker assays, are critical to fostering that understanding. Together, they are paving the way for scientists to better characterize the unique cancer cell populations, spatial relationships, and differences in immune responses in the tumor microenvironment.
In this GEN webinar, Michael Downing, Senior Image Analysis Scientist at Ultivue, will review the state of the field and introduce Ultivue’s two core platform technologies: InSituPlex® assays, and its proprietary Spatial Image Analysis pipeline featuring UltiStacker.AI™ and UltiAnalyzer.AI™. He will also explain how these technologies work together to provide high confidence insights from tumor data for scientists developing precision cancer therapies.
Topics covered in the webinar will include:
How AI-supported spatial image analysis together with Ultivue’s InSituPlex assays deliver accurate and scalable insights into the biology of the tumor microenvironment.
How Ultivue’s 12-plex assay verification demonstrates its readiness to provide a comprehensive view of the tumor microenvironment.
A live Q&A session will follow the presentation, offering you a chance to pose questions to our expert panelist.